You have 3 free guides left 😟
Unlock your guides
You have 3 free guides left 😟
Unlock your guides

Active targeting in nanobiotechnology enhances drug delivery precision. It uses , antibody-antigen binding, and to guide nanoparticles to specific cells. This approach improves therapeutic efficacy while minimizing .

Nanoparticle design plays a crucial role in active targeting. Surface , ligand density optimization, and spacer length adjustments are key factors. Common targeting ligands include antibodies, peptides, aptamers, and small molecules, each offering unique advantages for different applications.

Principles of active targeting

Ligand-receptor interactions

Top images from around the web for Ligand-receptor interactions
Top images from around the web for Ligand-receptor interactions
  • Ligand-receptor interactions involve the specific binding of a ligand molecule to its corresponding receptor on the target cell surface
  • Ligands can be natural or synthetic molecules (peptides, antibodies, aptamers) that have high for their receptors
  • Binding of the ligand to the receptor triggers cellular processes (endocytosis, signaling cascades) that facilitate nanoparticle uptake and intracellular delivery

Antibody-antigen binding

  • Antibodies are proteins produced by the immune system that recognize and bind to specific antigens with high affinity and
  • Monoclonal antibodies or antibody fragments can be conjugated to nanoparticles for targeted delivery to cells expressing the corresponding antigen
  • Antibody-antigen binding enables selective targeting of diseased cells (cancer cells expressing tumor-associated antigens) while minimizing off-target effects

Aptamer-target recognition

  • Aptamers are short, single-stranded oligonucleotides (DNA or RNA) that fold into unique three-dimensional structures capable of binding to specific targets with high affinity
  • Aptamers can be selected through an in vitro process called SELEX (Systematic Evolution of Ligands by EXponential enrichment) to bind to various targets (proteins, peptides, small molecules)
  • Aptamer-functionalized nanoparticles can recognize and bind to their targets on cell surfaces, enabling targeted delivery and enhanced cellular uptake

Nanoparticle design for active targeting

Surface functionalization strategies

  • Surface functionalization involves the attachment of targeting ligands to the nanoparticle surface to enable active targeting
  • Ligands can be conjugated to nanoparticles through various chemical methods (covalent coupling, physical adsorption, electrostatic interactions)
  • Common functionalization strategies include carbodiimide chemistry, maleimide-thiol coupling, and biotin-streptavidin interactions
  • Surface modification can also improve nanoparticle stability, , and stealth properties

Ligand density optimization

  • Ligand density refers to the number of targeting ligands present on the nanoparticle surface
  • Optimal ligand density is crucial for effective targeting, as too few ligands may result in insufficient binding, while too many ligands can lead to steric hindrance and reduced accessibility
  • Ligand density can be controlled by adjusting the ligand-to-nanoparticle ratio during the conjugation process
  • Higher ligand densities may enhance target binding and cellular uptake, but can also increase immunogenicity and clearance rates

Spacer length and flexibility

  • Spacers are molecules (PEG, peptides, polymers) that link the targeting ligand to the nanoparticle surface
  • Spacer length and flexibility can influence the accessibility and orientation of the ligand, affecting its ability to bind to the target receptor
  • Longer and more flexible spacers can improve ligand mobility and reduce steric hindrance, enhancing target recognition and binding
  • Spacer optimization can also help minimize nonspecific interactions and improve nanoparticle circulation time

Commonly used targeting ligands

Antibodies and antibody fragments

  • Monoclonal antibodies are widely used as targeting ligands due to their high specificity and affinity for their corresponding antigens
  • Antibody fragments (Fab, scFv) can be engineered to retain the targeting functionality while reducing the size and immunogenicity of the nanoparticle
  • Examples of antibody-targeted nanoparticles include Herceptin-conjugated for HER2-positive breast cancer and Cetuximab-functionalized for EGFR-overexpressing tumors

Peptides and proteins

  • Peptides are short chains of amino acids that can serve as targeting ligands by binding to specific receptors or antigens on cell surfaces
  • Peptides can be identified through phage display or rational design based on known receptor-ligand interactions
  • Examples of peptide-targeted nanoparticles include RGD-conjugated quantum dots for integrin-expressing tumor vasculature and transferrin-functionalized polymeric nanoparticles for transferrin receptor-mediated brain delivery

Aptamers and nucleic acids

  • Aptamers are synthetic oligonucleotides (DNA or RNA) that can fold into unique three-dimensional structures and bind to specific targets with high affinity and specificity
  • Aptamers can be selected through the SELEX process to target various or antigens
  • Examples of aptamer-targeted nanoparticles include AS1411-functionalized gold nanoparticles for nucleolin-expressing cancer cells and sgc8-conjugated carbon nanotubes for protein tyrosine kinase 7 (PTK7)-positive leukemia cells

Small molecules and vitamins

  • Small molecules, such as folate and biotin, can be used as targeting ligands due to their high affinity for specific receptors overexpressed on certain cell types
  • Vitamins, such as vitamin B12 and vitamin H (biotin), can also be employed as targeting moieties for receptor-mediated nanoparticle delivery
  • Examples of small molecule-targeted nanoparticles include folate-conjugated liposomes for folate receptor-overexpressing cancer cells and biotin-functionalized polymeric nanoparticles for biotin receptor-mediated oral drug delivery

Factors affecting targeting efficiency

Nanoparticle size and shape

  • Nanoparticle size influences its circulation time, extravasation, and cellular uptake, with smaller particles generally exhibiting better tissue penetration and faster clearance
  • Shape also affects nanoparticle interactions with cells and tissues, with spherical particles typically showing better uptake and longer circulation than non-spherical counterparts
  • Optimal size and shape depend on the specific application and target tissue, with sizes ranging from 10-200 nm and shapes including spheres, rods, and discs

Surface charge and hydrophobicity

  • Surface charge affects nanoparticle stability, interactions with serum proteins, and cellular uptake, with positively charged particles generally exhibiting better cell internalization but shorter circulation times due to rapid clearance
  • Hydrophobicity influences nanoparticle interactions with plasma proteins and cell membranes, with more hydrophobic surfaces leading to increased protein adsorption and faster clearance
  • Neutral or slightly negative surface charges and hydrophilic coatings (PEG) can improve nanoparticle stealth properties and prolong circulation time

Ligand affinity and specificity

  • Ligand affinity refers to the strength of the binding interaction between the ligand and its target receptor, with higher affinity generally resulting in stronger and more durable binding
  • Specificity refers to the ability of the ligand to distinguish between its target receptor and other similar molecules, with higher specificity reducing off-target binding and improving targeting efficiency
  • Ligand affinity and specificity can be optimized through rational design, directed evolution, or high-throughput screening methods

Receptor expression and accessibility

  • The level and pattern of target receptor expression on cell surfaces can greatly influence the effectiveness of active targeting
  • Higher receptor expression on target cells compared to healthy cells can enhance targeting specificity and minimize off-target effects
  • Receptor accessibility can be affected by factors such as tumor heterogeneity, vasculature permeability, and interstitial pressure, which can limit nanoparticle extravasation and distribution within the target tissue

In vitro evaluation of active targeting

Cell-based binding assays

  • Cell-based binding assays are used to assess the targeting ability of ligand-functionalized nanoparticles by measuring their binding and uptake by target cells expressing the corresponding receptor
  • Common techniques include flow cytometry, confocal microscopy, and radioligand binding assays
  • These assays can provide quantitative and qualitative information on nanoparticle-cell interactions, binding kinetics, and internalization mechanisms

Competitive inhibition studies

  • Competitive inhibition studies involve the use of free ligands or receptor-blocking antibodies to demonstrate the specificity of nanoparticle binding and uptake
  • By pre-incubating target cells with excess free ligands or blocking antibodies, the binding sites on the receptors are occupied, reducing the binding and uptake of targeted nanoparticles
  • These studies help confirm that nanoparticle uptake is mediated by specific ligand-receptor interactions rather than nonspecific mechanisms

Confocal microscopy and flow cytometry

  • Confocal microscopy allows for high-resolution imaging of nanoparticle binding and internalization by target cells, providing visual evidence of successful targeting
  • Nanoparticles can be labeled with fluorescent dyes or quantum dots to enable their detection and within cells
  • Flow cytometry enables rapid, quantitative analysis of nanoparticle binding and uptake by measuring the fluorescence intensity of individual cells
  • These techniques can be used to compare the targeting efficiency of different nanoparticle formulations and optimize their design

In vivo assessment of active targeting

Animal models and imaging techniques

  • In vivo assessment of active targeting involves the use of animal models (mice, rats) to evaluate nanoparticle biodistribution, tumor accumulation, and therapeutic efficacy
  • Imaging techniques such as fluorescence imaging, positron emission tomography (PET), and magnetic resonance imaging (MRI) can be used to visualize and quantify nanoparticle distribution in real-time
  • Xenograft tumor models are commonly used to assess the targeting and anti-tumor effects of nanoparticles in a living system

Biodistribution and pharmacokinetics

  • Biodistribution studies aim to determine the accumulation of targeted nanoparticles in various organs and tissues following systemic administration
  • Pharmacokinetic analysis involves measuring nanoparticle concentration in blood and tissues over time to determine their circulation half-life, clearance rate, and volume of distribution
  • Comparison of targeted and non-targeted nanoparticles can reveal the impact of active targeting on biodistribution and tumor accumulation

Tumor accumulation and penetration

  • Tumor accumulation refers to the ability of targeted nanoparticles to preferentially accumulate in tumor tissues compared to healthy organs
  • Tumor penetration involves the distribution of nanoparticles within the tumor mass, which can be limited by factors such as high interstitial pressure and dense extracellular matrix
  • Strategies to enhance tumor penetration include the use of smaller nanoparticles, matrix-degrading enzymes, and tumor-penetrating peptides

Therapeutic efficacy and safety

  • The ultimate goal of active targeting is to improve the therapeutic efficacy of nanoparticle-based drug delivery systems while minimizing side effects
  • In vivo studies can assess the anti-tumor effects of targeted nanoparticles loaded with chemotherapeutics, comparing them to free drugs or non-targeted formulations
  • Safety evaluation involves monitoring animals for signs of toxicity, such as weight loss, behavioral changes, and organ damage, to ensure that targeted nanoparticles do not cause adverse effects

Challenges and limitations

Immune recognition and clearance

  • Nanoparticles, especially those with non-self ligands or high ligand densities, can be recognized as foreign by the immune system and rapidly cleared from circulation
  • Opsonization, the adsorption of serum proteins onto nanoparticle surfaces, can promote phagocytosis by macrophages and other immune cells
  • Strategies to mitigate immune recognition include the use of stealth coatings (PEG), biocompatible materials, and lower ligand densities

Nonspecific binding and uptake

  • Despite active targeting, nanoparticles can still interact with non-target cells and tissues through nonspecific mechanisms, such as electrostatic interactions or protein adsorption
  • Nonspecific uptake by the reticuloendothelial system (liver, spleen) can reduce the bioavailability of targeted nanoparticles and increase the risk of off-target toxicity
  • Careful optimization of nanoparticle surface properties and ligand presentation can help minimize nonspecific interactions and improve targeting specificity

Heterogeneity of receptor expression

  • Tumor heterogeneity, both within and between patients, can lead to variable levels of target receptor expression on cancer cells
  • This heterogeneity can limit the effectiveness of active targeting, as nanoparticles may not be able to bind to and deliver drugs to all tumor cells equally
  • Combination targeting strategies, such as the use of multiple ligands or dual targeting of tumor cells and vasculature, may help address this challenge

Scale-up and manufacturing issues

  • The complex nature of actively targeted nanoparticles, with multiple components and functionalities, can pose challenges for large-scale production and quality control
  • Batch-to-batch variability, high costs, and regulatory hurdles can hinder the translation of targeted nanoparticles from the lab to the clinic
  • Advances in nanomanufacturing technologies, such as microfluidics and continuous flow synthesis, may help overcome these issues and enable the reproducible and cost-effective production of targeted nanoparticles

Clinical translation and applications

Cancer diagnosis and therapy

  • Active targeting has shown promise in improving the diagnosis and treatment of various types of cancer, including breast, prostate, and lung cancer
  • Targeted nanoparticles can be used to deliver imaging agents (fluorophores, radioisotopes) for early detection and monitoring of tumor growth and metastasis
  • Targeted delivery of chemotherapeutics, siRNA, or other therapeutic payloads can enhance drug accumulation in tumors while reducing systemic toxicity
  • Examples include HER2-targeted liposomes for breast cancer therapy and PSMA-targeted polymeric nanoparticles for prostate cancer imaging and treatment

Cardiovascular and inflammatory diseases

  • Active targeting can also be applied to the diagnosis and treatment of cardiovascular and inflammatory diseases, such as atherosclerosis and rheumatoid arthritis
  • Nanoparticles can be targeted to specific markers of inflammation (VCAM-1, selectins) or atherosclerotic plaques (αvβ3 integrin) for imaging and drug delivery
  • Examples include VCAM-1-targeted iron oxide nanoparticles for MRI detection of atherosclerotic plaques and selectin-targeted liposomes for the delivery of anti-inflammatory agents in rheumatoid arthritis

Neurological disorders and brain delivery

  • The blood-brain barrier (BBB) poses a significant challenge for the delivery of therapeutics to the central nervous system (CNS)
  • Active targeting of nanoparticles to receptors expressed on the BBB (transferrin receptor, insulin receptor) can facilitate their transcytosis and entry into the brain
  • Targeted nanoparticles can be used to deliver drugs, genes, or imaging agents for the diagnosis and treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and brain tumors
  • Examples include transferrin-targeted polymeric nanoparticles for the delivery of dopamine to the brain in Parkinson's disease and peptide-targeted gold nanoparticles for the imaging of amyloid plaques in Alzheimer's disease

Combination with passive targeting strategies

  • Active targeting can be combined with passive targeting strategies, such as the enhanced permeability and retention (EPR) effect, to further improve nanoparticle accumulation and retention in target tissues
  • The EPR effect relies on the leaky vasculature and impaired lymphatic drainage of tumors to promote the passive accumulation of nanoparticles in tumor tissues
  • By combining active targeting with the EPR effect, nanoparticles can initially accumulate in tumors through passive mechanisms and then bind specifically to target cells through ligand-receptor interactions
  • This combination approach can lead to synergistic improvements in tumor targeting, drug delivery, and therapeutic efficacy
© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.


© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.

© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.
Glossary
Glossary